Alterity Therapeutics (PRNAD) Common Equity (2009 - 2025)

Alterity Therapeutics (PRNAD) has reported Common Equity for 16 consecutive years, with $35.6 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Common Equity rose 599.79% year-over-year to $35.6 million; the TTM figure through Dec 2025 stood at $35.6 million (up 599.79% YoY), while the FY2025 annual figure was $27.2 million, up 198.64% from the prior year.
• Common Equity came in at $35.6 million for Q4 2025 at Alterity Therapeutics, up from $27.2 million in the prior quarter.
• The five-year high for Common Equity was $35.6 million in Q4 2025, with the low at $228129.1 in Q2 2023.
• Average Common Equity over 5 years is $19.0 million, with a median of $21.0 million recorded in 2021.
• Across the five-year window, Common Equity plunged 99.1% in 2023 and soared 5560.24% in 2024, its largest moves.
• Year by year, Common Equity stood at $30.0 million in 2021, then slumped by 38.37% to $18.5 million in 2022, then tumbled by 37.87% to $11.5 million in 2023, then slumped by 55.62% to $5.1 million in 2024, then jumped by 599.79% to $35.6 million in 2025.
• According to Business Quant data, Common Equity over the past three periods registered $35.6 million, $27.2 million, and $5.1 million for Q4 2025, Q2 2025, and Q4 2024 respectively.